Science — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Science Corporation is a private, clinical-stage medical technology firm pioneering biohybrid neural interfaces and brain-computer interface (BCI) systems. Its flagship technology is the PRIMA retinal implant, a subretinal microphotodiode array designed to restore vision in patients blinded by advanced geographic atrophy due to age-related macular degeneration, with breakthrough results published in The New England Journal of Medicine. The company is vertically integrated, developing the full technology stack from neural recording electronics to laser projection optics, and recently secured a $230 million Series C financing round to fund commercialization of PRIMA and expand clinical trials. Beyond vision restoration, Science is exploring a broader BCI ecosystem through partnerships and its 'Vessel' perfusion technology platform.

OphthalmologyNeurology

Technology Platform

Vertically integrated platform for biohybrid neural interfaces and brain-computer interface (BCI) systems, encompassing implantable microdevices (e.g., subretinal photovoltaic arrays), neural recording/stimulation electronics, laser projection optics, and wireless power/data transmission.

Opportunities

The lead PRIMA implant addresses a multi-billion dollar, completely unmet need in restoring vision for millions with advanced dry AMD.

Success here provides a launchpad to expand its vertically integrated BCI platform into a vast array of neurological disorders, including paralysis and communication deficits, representing a frontier market in medicine.

Strategic partnerships, like with Neurosoft, can accelerate ecosystem development and create additional revenue streams.

Risk Factors

High clinical and regulatory risk associated with a novel, permanently implantable Class III device.

Commercialization risk includes building surgical training, sales infrastructure, and securing adequate reimbursement.

Faces intense competition in the rapidly evolving neurotech space from well-funded private and public companies.

Competitive Landscape

In retinal implants, primary competitors include Pixium Vision (PRIMAMA system) and potentially others in research. In the broader BCI space, competition is fierce with companies like Synchron (endovascular BCI), Paradromics, Neuralink, and Blackrock Neurotech, alongside initiatives from large medtech firms. Science differentiates through vertical integration and its specific subretinal photovoltaic approach for vision.

More companies in Digital Health & Biotech SaaS →More companies in United States →